The search for the perfect animal model discloses the importance of biological targets for the treatment of systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 73, Issue 4, 2014, Pages 635-636

  Del Galdo, Francesco ^a   Matucci Cerinic, Marco ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR FRA 2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG CHOICE; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; EDITORIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN FIBROSIS; SKINFOLD THICKNESS; STUDY DESIGN; SYSTEMIC SCLEROSIS; TREATMENT PLANNING; VASCULITIS;

AUTOIMMUNE DISEASES; FIBROBLASTS; SYSTEMIC SCLEROSIS;

ANIMALS; FEMALE; HUMANS; MALE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84895450963     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203910     Document Type: Editorial

References (10)

1. Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-16. (Pubitemid 40385302)
2. Rosenbloom J, Jiménez SA. Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheum 2008;58:2219-24.
3. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
4. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011;63:3547-51.
5. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181:604-10.
6. Maurer B, Distler A, Dees C, et al. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis 2013;72:2039-46.
7. Manetti M, Rosa I, Milia AF, et al. Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma? Ann Rheum Dis 2013. Published Online First 12 Jul. 2013. doi:10.1136/annrheumdis-2013-203706
8. Jimenez SA, Piera-Velazquez S. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of Systemic Sclerosis and Sjögren's Syndrome. Autoimmun Rev 2013;12:1046-51.
9. Matucci-Cerinic M, Kahaleh B, Wigley FM. evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013;65:1953-62.
10. Seibold JR, Furst DE, Clements PJ. Why everything (or nothing) seems to work in the treatment of scleroderma. J Rheumatol 1992;19:673-6.